Product
Placebo Semaglutide
Aliases
Placebo semaglutide
4 clinical trials
4 indications
Indication
ObesityIndication
Pre-DiabetesIndication
Postpartum DisorderIndication
Type 2 Diabetes MellitusClinical trial
Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or ObesityStatus: Recruiting, Estimated PCD: 2025-01-27
Clinical trial
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityStatus: Active (not recruiting), Estimated PCD: 2024-10-21
Clinical trial
A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn With a Recent History of Gestational diabETes Mellitus: The SWEET StudyStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorStatus: Recruiting, Estimated PCD: 2025-11-26